These antibodies bind CD16A independently of the CD16A allotype, do not cross-react with the Fc binding site, thereby avoiding competition with the body’s own circulating serum IgG, do not exhibit NK cell fratricide, and bind to specific tumor cell antigens even when expressed at low levels. This evidence concerns the gene FCGR3A and neoplasm.